PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontneurologyLink to Publisher's site
 
Front Neurol. 2013; 4: 68.
Published online 2013 June 5. doi:  10.3389/fneur.2013.00068
PMCID: PMC3672779

The Serendipity Case of the Pedunculopontine Nucleus Low-Frequency Brain Stimulation: Chasing a Gait Response, Finding Sleep, and Cognition Improvement

Abstract

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an efficacious therapy for Parkinson’s disease (PD) but its effects on non-motor facets may be detrimental. The low-frequency stimulation (LFS) of the pedunculopontine nucleus (PPN or the nucleus tegmenti pedunculopontini – PPTg-) opened new perspectives. In our hands, PPTg-LFS revealed a modest influence on gait but increased sleep quality and degree of attentiveness. At odds with potential adverse events following STN-DBS, executive functions, under PPTg-ON, ameliorated. A recent study comparing both targets found that only PPTg-LFS improved night-time sleep and daytime sleepiness. Chances are that different neurosurgical groups influence either the PPN sub-portion identified as pars dissipata (more interconnected with GPi/STN) or the caudal PPN region known as pars compacta, preferentially targeting intralaminar and associative nucleus of the thalamus. Yet, the wide electrical field delivered affects a plethora of en passant circuits, and a fine distinction on the specific pathways involved is elusive. This review explores our angle of vision, by which PPTg-LFS activates cholinergic and glutamatergic ascending fibers, influencing non-motor behaviors.

Keywords: deep brain stimulation, Parkinson disease, neuromodulation, executive function, sleep structure

State-of-the-Art of Motor and Non-Motor Effects of PPN-DBS

Deep brain stimulation (DBS) of the Subthalamic nucleus (STN) has acquired the status of reliable therapy for Parkinson’s disease (PD) patients (Benabid et al., 2009; Moro et al., 2010a). However, in recent years, the neurosurgical treatment of movement disorders has been focused on identifying alternative targets to the traditional STN, in order to minimize adverse events and to rescue motor axial signs (Pahapill and Lozano, 2000; Nandi et al., 2002b; Mena-Segovia et al., 2004; Stefani et al., 2007). In fact, although the efficacy of STN-DBS on segmental motor symptoms is proved, other motor features (akinesia, freezing of gait) are relatively resistant to STN-DBS or may even worsen (Kleiner-Fisman et al., 2003; Rodriguez-Oroz et al., 2005). Incidentally, the benefits promoted by DBS of the ventromedial tiers of the globus pallidus internus (GPi), too rapidly abandoned in the nineties, were similar to those obtained by STN-DBS, and were scarcely impressive on gait (Rodriguez-Oroz et al., 2005; Follett et al., 2010).

The pedunculopontine nucleus area (PPN-a) represents an heterogeneous structure placed in the dorso-lateral mesopontine tegmentum; it consists of a pars compacta and a pars dissipata and features a complex cells organization, which engages different population of cholinergic, glutamatergic, and GABAergic neurons (Mena-Segovia et al., 2009; Wang and Morales, 2009). As known, PPN-a, part of the reticular activating system, plays a critical role in regulating the sleep-awake cycle and facilitating arousal mechanisms (Steriade et al., 1990a; Rye, 1997; Datta, 2002). PPN-a is also strongly involved in other facets of behavior including motivation, attention, reward, and mnemonic processes (Steckler et al., 1994; Winn, 2006; Andero et al., 2007; Ros et al., 2010).

In addition, it has been largely inferred that portions of PPN-a participates in locomotion and contributes to postural tone as a result of the influence on the lower brainstem and on the spinal cord, exerted via the pontomedullary reticular formation and reticulospinal nuclei (Lee et al., 2000; Pahapill and Lozano, 2000; Takakusaki et al., 2003; Mena-Segovia et al., 2004; Pierantozzi et al., 2008). Experimental models proved that “some dorsal tiers” of the PPN-a, i.e., the traditional mesencephalic locomotor region, induces initiation, and maintenance of locomotion (Garcia-Rill et al., 1987; Skinner et al., 1990; Takakusaki, 2008), while its inactivation, by lesion or high frequency stimulation (HFS), produces akinesia in non-human primates (Munro-Davies et al., 1999; Nandi et al., 2002b). It should be noted that this form of experimental akinesia may be reverted by the low-frequency stimulation (LFS) of PPN-a (Nandi et al., 2002a,b; Jenkinson et al., 2004). Moreover, extensive degeneration of PPN-a occurs in idiopathic PD (Hirsch et al., 1987; Pahapill and Lozano, 2000). An adjourned excursus of the complex functional organization of PPN region is available in the review by Benarroch (2013).

All this considered, PPN-a was envisioned as a good and safe candidate for stereotactic neurosurgery in PD patients featuring prominent and levodopa-resistant axial impairment (Pahapill and Lozano, 2000; Mena-Segovia et al., 2004; Pereira et al., 2008). The pioneering works were performed by an Italian and a British group (Mazzone et al., 2005; Plaha and Gill, 2005). Mazzone has renamed further his preferential target as the nucleus tegmenti pedunculopontini (PPTg) (Mazzone et al., 2007, 2008, 2011). For reasons of clarity, from now on, the definition PPTg will be utilized for works produced by the Italian specialists, whilst PPN-a will be maintained for all the others.

Since then, other groups successfully completed the neurosurgical procedure targeting either bilateral or mono-lateral PPN-a, in limited series of selected PD patients. Table Table11 illustrates most of the available works worldwide (choice was not limited to, but oriented toward, those manuscripts capable to illustrate also non-motor domains).

Table 1
Selected papers on PD patients implanted in the “PPN-area” (estimated 60 patients from Rome, Bristol, Oxford, Melbourne, Grenoble, Toronto).

The fascinating proposal that PPN-a-LFS might represent the alternative surgical strategy to manage some Parkinsonian motor symptoms inadequately responsive to traditional DBS targets, has not been confirmed in full (Stefani et al., 2007; Ferraye et al., 2010; Moro et al., 2010b). Recent clinical follow-ups at 2–3 years reported some uncertainties (Moreau et al., 2009; Peppe et al., 2010) or a progressive decline of the transient gait amelioration (in support of likely placebo effect, see Stefani et al., 2009). Despite these inconsistencies, Mazzone and co-authors have documented lately a solid procedure in more than 15 patients mono-laterally implanted in PPTg (thus, a procedure not including the simultaneous targeting of STN – consider Table 2 in Mazzone et al., 2011, from patient 7 to patient 23, plus additional 5 more in recent months); hence, more extended follow-up in a larger patient sample is ahead.

Our first observations (Stefani et al., 2007), focused on the PPTg-LFS (10–25 Hz) in PD patients simultaneously implanted in STN, showed some disappointing motor results (at least if compared to 130–185 HFS-STN), but opened new interesting perspectives in terms of beneficial impact on PD non-motor symptoms (NMS), including sleep, attention, and cognitive domains (Alessandro et al., 2010; Costa et al., 2010).

In the last decade, huge efforts in the neurological community have been devoted toward detection and classification of NMS in PD patients, since recognized as a detrimental milestone, which may dictate patient quality of life (Chaudhuri et al., 2006; Hinnell et al., 2012). Accordingly, nowadays the majority of on-going, long-lasting clinical trials include measures of global cognitive functioning and psychopathological profiles, especially if designed to assess the efficacy of complex therapeutic strategies such as DBS (Witt et al., 2008, 2011). Interestingly, in PD patients undergoing STN-DBS, the best motor response was not necessarily correlated to the increase of metabolic activity in frontal cortical areas governing executive functions. STN-DBS was found to partly restore physiologic glucose consumption in limbic and associative projection territories of the basal ganglia, but erratically (Hilker et al., 2004). Overall, a minimal decline – albeit frequently infra-clinical – of cognitive and executive functions may occur after STN-DBS (Parsons et al., 2006; Witt et al., 2008; Daniels et al., 2010). This figure is hard to attribute in full to the STN-HFS per se, given the natural PD history, which implies: (a) a continuous decline of dopaminergic function as the disease progresses, independently of pharmacological or surgical treatments (Hilker et al., 2005) and (b) the progressive involvement of other pathways (noradrenergic and cholinergic ones).

This scientific field around PPN-a is largely perturbed by a long-lasting debate concerning appropriateness and functional anatomy of the brain-stem targeting, as we have presented (Mazzone et al., 2005, 2008, 2011; Stefani et al., 2007). In our patients, the stimulation target did in fact correspond to the caudal pontine representation of PPN, which is PPTg (Mazzone et al., 2008; Insola et al., 2012) and, likely, coincides, at least in part, with PPN pars compacta (PPN-C, see Figure 1 in Benarroch, 2013). Contenders have questioned this localization; the Queen’s Square group proposed, for instance, a careful approach to identify an ideal stereotactic localization of the nucleus (Zrinzo et al., 2008). At present, the perfect PPN-DBS surgical strategy still waits for further investigations, and we may hope that the academic discussion avoids some crude, occasionally too informal a tone, recently topping the standard dialectics (Aviles-Olmos et al., 2011; Mazzone et al., 2012a).

In the patient’s interest, any group is expected to provide unequivocal correlations between target details and clinical scores. Mazzone et al. (2011) have recently addressed the potential ambiguities via a careful reassessment of the target, based upon an unconventional reconstruction, which overcomes the routine CA-CP landscape and focuses on dedicated landmarks of the brain-stem.

Also the Grenoble group provided a patient-by-patient MRI identification of the target (Ferraye et al., 2010), but acknowledged the variability of the clinical response and the lack of a strict correlation between catheter positioning and gait performance. The French school had initially utilized micro-recording through a rostro-caudal trajectory starting from CA-CP line toward the “para-cuneiform” region, in which a generous “mimicked gait”-firing discharge occurred (consider Piallat et al., 2009). However, similar electrophysiological hallmarks are not shared by others.

For the time being, at least five groups worldwide have chased the PPN-a as potential target (Table (Table1).1). Unfortunately, the lack of common protocols has hampered from the beginning the chance to acquire solid conclusions despite the small number’s series. In particular, cognitive evaluations are not always available or appear as anecdotal. Also in terms of the motor outcome, so far, results are inconclusive.

In this scenario, the modest, but consistent, cognitive amelioration induced by PPN-a-LFS, at least in our patients, is of interest, representing the core of the following chapters.

PPN-Area DBS and Sleep

Pedunculopontine nucleus area is undoubtedly involved in controlling alternations between behavioral states as the result of promoting the thalamo-cortical activation that is thought to regulate both wakefulness and rapid eye movement (REM) sleep in mammals (Rye, 1997; Pahapill and Lozano, 2000). Not surprisingly, different research groups, who have experienced PPN-DBS in an attempt to improve Parkinsonian motor symptoms, have ascertained the impact of 10–70 Hz PPN-stimulation on patients’ sleep quality.

In our hands, PPTg stimulation proved a potent effect on patient sleep architecture, as originally emphasized by a pioneering Polysomnography (PSG) study (Romigi et al., 2008), whose results were subsequently replicated (Alessandro et al., 2010). In these studies, we investigated the specific effect of bilateral PPTg-DBS on sleep structure of two PD patients by means of PSG recordings, which were performed before and after surgery (STN-ON/PPTg-OFF versus PPTg-ON/STN-OFF). The PSG data documented that, before surgery, PD patients featured a severe sleep architecture disruption, with frequent occurrence of nocturnal awakenings, increased Stage I sleep and wakefulness after sleep onset (WASO), plus a remarkable reduction of REM sleep time. In comparison with pre-surgery, both bilateral STN-DBS and PPTg-DBS induced the striking improved of sleep efficiency, with reduction of WASO and nocturnal awakenings, together with a mild reduction of Stage 1 and increase of Stage 2 sleep. However, whereas STN-DBS had no impact on REM sleep, only PPTg-DBS promoted a reduction of REM latency and a relevant increase in REM sleep time (Romigi et al., 2008; Alessandro et al., 2010).

These first PSG findings were soon confirmed by a successive electrophysiological study carried out in three PD patients and two patients affected by progressive supra-nuclear palsy (PSP) undergoing unilateral PPN-a DBS for prominent extra-pyramidal axial signs (Lim et al., 2009). In all those patients, it was found that PPN-a DBS, at both higher (70 Hz in PSP patients) and lower (5–30 Hz in PD patients) frequency stimulation, increased REM sleep time and REM percentage by inducing more REM sleep periods, possibly lowering the REM sleep threshold.

Although the local neuronal effects of DBS are still not fully understood, the physio-pathogenesis of these PSG results may be explained by considering that REM sleep is regulated via reciprocally inhibitory REM “ON” and REM “OFF” nuclei, located into the pontomesencephalic tegmentum (McCarley and Hobson, 1975), and that the PPN-a may promote REM by modulating a brain-stem “flip-flop” switch, represented by the REM “ON” sublaterodorsal and precoeruleus regions, and the REM “OFF” lateral pontine tegmentum and ventrolateral periaqueductal gray (Lu et al., 2006). In these patients, the active stimulating electrodes were located into or near the PPN pars dissipata, and the frequency of stimulation utilized was relatively low (5–70 Hz). Hence, it has been inferred that PPN-a-ON may act on REM sleep by increasing output from the REM “ON” PPN neurons, and trans-synaptically inhibiting the REM “OFF” ventrolateral periaqueductal gray (dorsomedial to PPN) and lateral pontine tegmentum (lateral to PPN) region. In fact, LFS, in contrast with HFS, could increase the firing discharge of neurons next to the electrode (i.e., REM “ON” neurons), and excites, at the same time, inhibitory pre-synaptic afferents to neurons at some distance from the electrode (i.e., REM “OFF” neurons) (Johnson et al., 2008). Moreover, an electrical coupling between PPN-a neurons and both the parafascicular intralaminar nucleus and the subcoeruleus nucleus, equally involved in cortical activation and REM sleep regulation, has been recently demonstrated as a novel mechanism for sleep-awake control. The finding of electrical coupling in a specific area of the reticular activating system endorses the concept that this underlying process, behind specific neurotransmitter interactions, modulates the firing activity across different cell populations to induce changes in sleep-wake state (Garcia-Rill et al., 2007; Heister et al., 2007).

It is well known that PPN-a, part of the reticular activating system, is characterized by powerful ascending cholinergic projections to the associative and non-specific intralaminar thalamic nuclei, counting the centrolateral and the parafascicular neurons (Kobayashi and Nakamura, 2003; Parent and Descarries, 2008), which participate in modulating waking and REM sleep (Datta, 2002; Datta and Siwek, 2002). Within the thalamo-cortical systems, the PPN-cholinergic neurons, characterized by low (less than 10 Hz) and high (20–80 Hz) rates of spontaneous tonic firing, exhibit their maximal firing activity during both REM sleep and waking, which are associated with desynchronization of the electroencephalogram (EEG) (Steriade et al., 1990a,b; Datta et al., 2002). On the basis of PPN-a specific firing properties, intracellular recordings in animal models identified different types of thalamic projecting PPN-cholinergic cells, which are strictly related to the genesis of the ponto-geniculo-occipital (PGO) waves, and thus to the generation of REM sleep and REM sleep dependent cognitive function (Steriade et al., 1990b; Datta et al., 2002; Datta, 2006). Indeed, PGO waves are recorded during and immediately before REM sleep from the pontine reticular formation, lateral geniculate, and occipital cortex and represent the neurophysiological index of mammalian REM sleep (Callaway et al., 1987). Intracellular injection of cholinergic agonists (and/or kainate receptor) demonstrated that kainate receptor agonists were able to increased REM sleep, and at the same time, to generate PGO waves as a consequence of the increased activity of PPN-cholinergic neurons (Datta, 1997; Datta et al., 2002).

Aside these experimental studies, a recent elegant electrophysiological study carried out in a PD patient undergoing to unilateral PPN-a DBS (Lim et al., 2009) supported the evidence that PPN-stimulation exerts a possible REM-promoting effect. In this patient, phasic potentials were simultaneously recorded from the intrapontine depth DBS electrode and the scalp electrodes (24-h video-PSG). These potentials have been identified exclusively before and during the REM sleep, being partially associated to the eye movement. Moreover, their morphology, temporal distribution, and localization were similar to those of PGO waves occurring in other mammals, since their origin was recognized in a restricted region of the pontomesencephalic tegmentum and were invariably followed by characteristic cortical potentials with a latency of 20–140 ms. Taken together, these electrophysiological data support the hypothesis that these waveforms correspond to the pontine component of humans PGO waves and that the PPN-a represent the PGO transferring regions (Datta, 1997).

In a recent clinical study, performed in two PD patients undergoing bilateral PPN-a DBS, it was observed that in awake state PPN-a at 80 Hz induced sleep (Arnulf et al., 2010). Therefore, to substantiate this clinical observation, a daytime PSG was performed at different stimulator settings maintained for at least 5 min each with a 3-min stimulator deactivation between changes in settings. PPN-a-LFS (10–25 Hz) promoted wakefulness in the two patients, while PPN-a-HFS (80 Hz) induced sleepiness and, thus, non-REM sleep (within 0.5–8 min). These data indicate that LFS and HFS of PPN-neurons strongly modulate the activity of the nucleus and its connections, resulting in opposite effects on sleepiness and alertness. Unexpectedly, the same study also showed that in one out of the two patients, the brisk ending of PPN-a-LFS caused fast sleep onset and REM sleep within 3–6 min, which lasted 2.6–9 min, to be followed by spontaneous wakefulness. The precise origin of the unexpected of REM sleep induction after abrupt withdrawal of LFS remains unclear, although the authors stated that a more dorsal placement of the stimulator electrode took place (Arnulf et al., 2010).

In a more recent study, we have investigated further the long-lasting effects of PPTg-DBS (the definition chosen for our target, as suggested in the introduction) on nocturnal sleep and diurnal somnolence in five PD patients (Peppe et al., 2012). Of course, they are still the patients of the original series (neurosurgical procedure including targeting in both PPTg and STN, Stefani et al., 2007).

This latter analysis was focused on subjective sleep scales, including the Parkinson’s disease sleep scale (PDSS), a specific and comprehensive pragmatic clinical tool designed to address the multi-factorial nature of sleep disturbances in PD (Chaudhuri et al., 2002), and the Epworth sleepiness scale (ESS), an eight-item self-reporting questionnaire assessing symptoms of diurnal drowsiness (Johns, 1991). Following the study design, scales were administered a week before surgery and then 3 months and 1 year after surgery. Maintaining constantly ON the STN-DBS for ethical concerns, the investigation required three different patterns of PPTg-DBS, each kept for 15 days: (1) condition OFF; (2) condition ON (PPTg stimulated 24 h a day); condition CYCLE (PPTg stimulated 12 h at night). The most interesting results can be summarized as it follows: (i) a significant improvement of nocturnal sleep quality was observed at 3-month follow-up and, then, confirmed at 1-year follow-up in comparison to pre-surgery (true in all DBS conditions, although prominent during PPTg cycle stimulation; (ii) only PPTg-DBS, unlike STN-DBS, induced a remarkable long-term improvement of patient daytime sleepiness, as testified by the significant reduction of ESS score at 1-year follow-up (Figure (Figure2);2); (iii) the cyclic PPTg-DBS proved more efficacious than the continuous one on some aspect of nocturnal sleep, including nocturnal restlessness and psychosis (more details on PDSS and ESS data can be found in Peppe et al., 2012). For the scopes of this review, it is noteworthy that even the Pittsburgh sleep quality index (PSQI), a self-rated clinical scale considered an indicator of relevant sleep disturbances in general population (Buysse et al., 1989), proved the positive influence of PPTg-DBS on sleep-awake cycle. In fact, PSQI showed a remarkable and long-lasting improvement of patient global sleep quality after surgery, mostly noticeable during PPTg-DBS, as demonstrated by the significant reduction of PSQI score observed after surgery (Figure (Figure1).1). Based on the different PPTg stimulus modalities explored, we indicated the importance of stimulating this area during sleep, showing that cyclic stimulation of the PPTg reveals a better efficacy on PD patients’ sleep quality than the continuous one. Hence, we hypothesized that the amelioration of sleep-awake cycle, clearly evident after the 3-month follow-up (but more under CYCLE), could be due to greater physiological stimulation of PPTg activity. The fact that we found the same results (similar impact on daily somnolence) with both stimulation (ON and CYCLE), at the 1-year follow up, suggests a sort of ceiling effect. Finally, considering that the same two patents who underwent PSGs study, showed a remarkable reduction of EES score during PPTg-DBS, it is interesting to hypothesize a relationship between the improvement in daytime sleepiness and the amelioration of REM sleep, especially considering the PPTg central role in promoting arousal in addition to REM sleep (Rye, 1997).

Figure 1
Exemplary FDG consumption comparing, in the same PD subjects, the condition only PPTg-ON (left panel) versus the condition STN-ON (imaging were performed in Pisa, under the supervision of Dr. Ceravolo and Dr. Volterrani; for details, see Ceravolo et al., ...
Figure 2
Shown are mean results of Epworth sleepiness scale (ESS) in original PD patients implanted a long-time ago (2006–2007) in both STN and PPTg. Histograms refer to before surgery (T0), then 3 (T1), and 12 months (T2) following surgery completion. ...

In conclusion, few studies have been performed in PD patients to assess the objective and subjective changes in sleep-awake cycle related to PPN-a DBS. Moreover, comparison of data is difficult since they were carried out in a small number of subjects, following different surgical approaches and electrode placement and using diverse stimulus parameters. Nevertheless, apart from possible discrepancies in patients’ motor outcome, there is a converging evidence that PPN-DBS exerts a positive effect on sleep quality and wakefulness as well as on nocturnal REM sleep, indicating the central role of PPN-a in sleep physiology and sleep dysfunction in humans, as previously documented from experimental studies.

Noteworthy, and despite our fascination around PPTg-mediated effects on sleep, several therapeutic agents exist already for advanced PD patients suffering alterations of sleep architecture, and DBS should never represent a short-cut indication for this sort of impairments.

PPN and Cognition

In our hands, PPTg-DBS, originally conceived as a strategy for PD gait impairment, revealed a little influence on postural instability and gait impairment, but regularized sleep and influenced cognitive performance. As a matter of fact, the contribution of PPTg-LFS in changing gait parameters was not significant with respect to STN-HFS (Moreau et al., 2009; Peppe et al., 2010). Yet, both Toronto’s and Grenoble’s groups found more appealing and consistent results in their patient cohorts, with a single mono-lateral target (Ferraye et al., 2010; Moro et al., 2010b).

Our initial observations (Mazzone et al., 2005, 2007; Stefani et al., 2007) concerned PD patients under a double target protocol (PPTg plus STN) and the following biases are possible: first, the implantation of multiple electrode catheters might contribute to severe stereotactic “lesion-effect” (yet, negligible in the long run); second, and more critical, is a sort of tautology: that the enrollment criteria utilized once, in recruiting patients for such a novel and potentially risky surgery, were influenced more by patient’s motivation and absence of co-morbidity rather than the severity of LD-resistant sings (i.e., axial) and or the presence of freezing of gait (FOG, see Stefani et al., 2007). At least two of our first patients were indeed recruited despite disease duration <10 years and despite scarce FOG. In other words, how could it be possible to judge the specific PPN-mediated influence on FOG in PD patients manifesting only a modest degree of axial akinesia and/or the rare incidence of falls (whilst it was statistically more pronounced in PD confined to the wheelchair or experiencing several weekly falls)? Accordingly, it is still possible, as advocated by others, that the PD patients with an extremely severe postural imbalance and an akinetic profile less responsive to conventional drug therapy may be ideal candidates for surgery aimed at implanting the pontine structures. Moro et al. (2010b) have shown convincingly the clear reduction of falling episode in the 1-year follow of mono-laterally implanted PPN. In the Grenoble series, gait analysis results were also promising (Ferraye et al., 2010, 2011). Mazzone is proceeding with an extensive series of mono-lateral PPTg and gait results seem more consistent (personal communication).

For the purpose of this review, PPTg-LFS, in our patients, proved to have a potent effect on degree of attentiveness and some specific cognitive performances. At odds with some adverse events observed following STN-DBS (i.e., worsening of semantic and phonemic fluency), PD patients under PPTg-LFS may experience a significant amelioration of delayed recall, executive functions and verbal fluency (Alessandro et al., 2010; Costa et al., 2010; Ceravolo et al., 2011).

As recalled (Mazzone et al., 2011), “PPN lesion, in animals, impairs attention, executive function, working memory (WM), and learning” (on this issue, consider the pioneering review by Anderson et al., 2006; Winn, 2006). However, anatomists suggested that an abundant 30% PPN already degenerate in the early PD disease stages; apoptotic-like processes affect the PPN neuropil and may represent a hallmark of extra-pyramidal syndrome. Hence, how is it possible that DBS of a degenerated area is promoting any effect? Reasonable answers include the preferential activation of PPN-fugal axonal fibers and the maintained functional roles of surviving PPN neurons (Scarnati et al., 1987; Florio et al., 2007).

The relevance of these findings emerges if compared to the cognitive outcome of standard targets. Careful neuropsychological examination in STN-implanted subjects may in fact disclose a large percentage of subtle deficits in the post-surgery follow-up. Some authors, at one extreme, demonstrated that >30% of STN-DBS patients experienced a cognitive decline sufficient to identify conversion to dementia (Williams et al., 2011). This finding represents a warning, although it did not reach significance with respect to PD not submitted to neurosurgery (Williams et al., 2011).

Are these deficits really and promptly impacting any patient’s quality of life? Prolonged trials, conducted on patients implanted also at younger age (consider the series by Castrioto et al., 2011 and see Vitek, 2012) or preliminary data from the early stim group, a multi-center investigation on about 150 early onset PD, suggest not overestimating this issue (Schuepbach et al., 2013).

Nevertheless, an honest reappraisal of the literature about STN-DBS, even if performed by unbiased experts, admits the potential increase of apathy, and some degree of impairment in non-verbal recall, oral information processing speed, and semantic fluency (Bronstein et al., 2011).

In this content, the PPN-mediated cognitive benefits are remarkable, despite the small cohort and the relatively modest effect.

We found no significant changes between pre-surgery and PPTg-OFF/STN-OFF conditions (Ceravolo et al., 2011). Conversely, the condition PPTg-ON/STN-OFF significantly improved cognition in different domains when compared to PPTg-OFF/STN-OFF. PPTg-ON ameliorated verbal long-term memory, assessed with the California Verbal Learning test delayed recall (p < 0.025), and executive functions, as revealed by both TMT (B-A p < 0.025) and verbal fluency (p < 0.001). Therefore, we did conclude PPTg-DBS “fueled a significant cognitive improvement” (Ceravolo et al., 2011).

Costa et al. (2010), in another study (Table (Table1),1), investigated the WM functioning in the same subjects (five PD patients who underwent simultaneous PPTg- and STN-DBS). PD patients were evaluated (in the morning at least 12 h after antiparkinsonian therapy withdrawal) comparing two conditions: (i) after continuous PPTg stimulation (OFF Therapy/ON PPN); (ii) 120 min after PPTg had been switched “OFF” (OFF Ther/OFF PPN). The experimental WM task consisted of an n-back paradigm with verbal and visual-object stimuli. PD patients manifested “a consistent response time decrease on both the verbal and the visual-object tasks under the PPTg-ON condition (p < 0.05).” However, the accuracy score did not significantly differ between the two experimental conditions. It was suggested that PPTg-stimulation “facilitates the speed of processing of information in the content of WM, possibly through the modulation of the attentional resources” (Costa et al., 2010).

As a corollary study, Zanini explored the possibility that combined STN-HFS and PPTg-LFS influenced language. This study observed “an interesting trend toward reduction of ungrammatical errors (particularly substitution of free and inflectional morphemes)” when stimulating either STN (at 130 Hz) or PPTg at 20 Hz (Zanini et al., 2009; Table Table11).

Which mechanisms may underlie this surprising pattern of effects? Figure Figure11 compares paradigmatic PET, performed on the same PD subject, before and during either STN-ON (180 Hz) or PPTg-ON (25 Hz) (Figure (Figure1).1). Such an extended and bilateral activation of several cortical areas (including medial frontal structures) is intuitively detected. The most relevant findings could be summarized as follows:

  • -
    An extensive and bilateral metabolic activation of several cortical regions, including both medial and dorso-lateral area of the frontal lobe (Figure (Figure11);
  • -
    The mono-lateral activation of the ventral striatum (Figure (Figure11);
  • -
    The decrease of metabolic activity in the left anterior cerebellum (culmen, not shown) (Alessandro et al., 2010; Ceravolo et al., 2011).

However, to date, other groups, utilizing since the late 2000s a mono-lateral (and more medial) target inside PPN-a, emphasized rather different metabolic results (acquired with different technique). Strafella and co-authors described mostly a PPN-mediated increase of metabolic activity – rCBF changes – on viciniori GPi and thalamus (Strafella et al., 2008; Ballanger et al., 2009).

A possible limitation of our studies concerns the lack of comparative evaluations of the condition PPTg-ON versus pharmacological ON-state. Another bias could derive from the fact that few consistent data are available, at present, on low-frequency STN-related changes of cortical metabolic activity. Hence, there is not sufficient ground to exclude, albeit unlikely, that a low-frequency STIM of STN might re-propose metabolic changes similar to PPTg (Stefani et al., 2010). A very recent contribution suggested, in four patients with bilateral PPN and caudal zona incerta (cZi) DBS electrodes that combined PPN/cZi stimulation produced a statistically significant improvement in UPDRS-III score compared to cZi stimulation alone, but only in the condition MED-ON (Khan et al., 2012). Interestingly, “the concomitant PPN/cZi stimulation had a cumulative effect on levels of rCBF, effectively combining sub-cortical and cortical changes induced by stimulation of either target in isolation” (Khan et al., 2012).

Conclusion

Limited experience worldwide impedes the drawing of conclusive statements on the clinical efficacy of PPTg stimulation on both motor and non-motor domains. Any straightforward assumption is, in our opinion, quite presumptuous. Major effort should be launched for assessing to what extent the impact on sleep and cognition, as detailed in our hands, may in fact be replicated by other teams utilizing different trajectories; for the time being, whether some of the NM benefits described (i.e., changes of sleep structure) are really target-dependent and/or, at least in part, frequency-dependent, might be addressed. In addition, the significance of clinical changes in cognitive performance need to be evaluated in light of real changes in routine functional way of life (as explored on dementia in Stefani et al., 2013). On-going studies and extended follow-up will contribute at clarifying this issue.

Unfortunately, as we acknowledged, the current technologies do not support the attribution of a specific effect to any specific contact lead and it is difficult to speculate on which sub-cortical pathways (Aravamuthan et al., 2007, 2008) or spinal circuitry is involved, since the commercially available catheters affect a-specifically a plethora of en passant circuits. Yet, and despite rather different targets, the LFS of the “PPN region” implanted by Bristol (Khan et al., 2012) and Rome (Ceravolo et al., 2011) seems to provide quite similar impacts on cortical metabolism.

With the present procedures, nobody has ascertained, so far, to what extent stimulation of PPN preferentially modulates and/or activates specific neuronal phenotypes (gabaergic, glutamatergic, cholinergic) or fibers.

That said, the pattern of responses detected in our original cohort may be attributed to more selective activation of the pontine cholinergic contingent (abundant in PPN-C/PPtg) and explain the robust effect on sleep and behavioral state. In contrast, a more selective activation of dorsal and medial sub-regions (likely targeted by Toronto’s and Grenoble’s series) may indeed reflect into discrete regional activation of nearest basal ganglia stations (Strafella et al., 2008) and solid effects on falls prevention (Ferraye et al., 2010; Moro et al., 2010b; Thevathasan et al., 2012).

One critical aspect to mention is that the PPN region, in PD patients as well as in atypical Parkinsonism, is affected by severe neuro-pathological abnormalities; a loss of a 30–40% neurons is supported by post-mortem studies. We are tempted to speculate that large differences in clinical response might be attributed not to neuro-functional targets per se but also to neuro-pathological differences between patients, for example in terms of the severity of cholinergic neuronal loss, correlated in turn with the severity of axial symptoms (Rinne et al., 2008).

In other words, some discrepancies between groups (or even in the same patient’s series) are possibly explained by the different degree of PPN neuronal loss as manifested along the ponto-mesencephalic axis in each patient submitted to surgery. We know that the “the activity of thalamic-projecting cholinergic neurons of the PPN is consistent with their role in inducing and maintaining thalamo-cortical activation associated with desynchronization of the EEG during wakefulness and REM sleep” (Steriade et al., 1990; Benarroch, 2013). What we do not know, of course, is the abundance of the residual not degenerated contingent of fibers potentially activated by LFS in each of our patients.

Although results between groups appear divergent in many respects, 6 years experience on PPN-a/PPTg stimulation, in humans, corroborates the following statements:

  1. Clinical results support the hypothesis that single, mono-lateral PPTg-LFS is advisable and safe, as originally advocated by Toronto’s group (Moro et al., 2010b);
  2. The “pro-attentive pattern,” promoted by PPTg-ON in our first series, is very peculiar if compared to detrimental or negligible cognitive effects promoted by routine STN-HFS. This may suggest that endogenous transmitters other than catecholamines are involved when PPTg (and PPN-a in a broad sense) was stimulated. In our opinion, a widespread activation of ascending pathways (mostly cholinergic fibers toward intra-thalaminar nuclei) is the key factor. The unequivocal demonstration would demand verification, through micro-dialysis, of the on-going release of Ach or catecholamines or the modulation of trophic factors and/or nucleotides in main target areas of PPN-a (such as GPi/SNr on one hand and CM/Pf on the other) (see for example Fedele et al., 2001; Stefani et al., 2005, 2011).
  3. The relevance of the PPTg-mediated benefits on the NM spectrum signs is intriguing and supports, albeit speculatively, the working hypothesis that the stimulation of specific sub-portions of the pontine tegmentum should be tested as a therapeutic chance in severe extra-pyramidal syndrome, such multi-system atrophy (Brusa et al., 2009; Mazzone et al., 2012b), or neurological states dominated by vigilance defects.

Our original contention – PPTg as a potential trigger to fuel endogenous circuitries targeting large thalamic and cortical areas – might be either validated or decline in a few years, provided that a combination of technically refined approaches, adjourned peri-surgical imaging, better application of neuro-physiological hallmarks in the postsurgical phase and data acquisition from larger series take place.

Preliminary Disclosure

This manuscript does not represent an evidence-based review and, of course, it contains many subjective opinions. Only a larger observations, a more extended follow-up and, possibly, shared neurosurgical parameters, would allow, in the next future, more clear conclusions.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • Alessandro S., Ceravolo R., Brusa L., Pierantozzi M., Costa A., Galati S., et al. (2010). Non-motor functions in parkinsonian patients implanted in the pedunculopontine nucleus: focus on sleep and cognitive domains. J. Neurol. Sci. 289, 44–48. doi: 10.1016/j.jns.2009.08.017. [PubMed] [Cross Ref]
  • Andero R., Torras-Garcia M., Quiroz-Padilla M. F., Costa-Miserachs D., Coll-Andreu M. (2007). Electrical stimulation of the pedunculopontine tegmental nucleus in freely moving awake rats: time- and site-specific effects on two-way active avoidance conditioning. Neurobiol. Learn. Mem. 87, 510–521. doi: 10.1016/j.nlm.2006.11.002. [PubMed] [Cross Ref]
  • Anderson H. L., Latimer M. P., Winn P. (2006). Intravenous self-administration of nicotine is altered by lesions of the posterior, but not anterior, pedunculopontine tegmental nucleus. Eur. J. Neurosci. 23, 2169–2175. doi: 10.1111/j.1460-9568.2006.04737.x. [PubMed] [Cross Ref]
  • Androulidakis A. G., Mazzone P., Litvak V., Penny W., Dileone M., Gaynor L. M., et al. (2008). Oscillatory activity in the pedunculopontine area of patients with Parkinson’s disease. Exp. Neurol. 211, 59–66. doi: 10.1016/j.expneurol.2008.01.002. [PubMed] [Cross Ref]
  • Aravamuthan B. R., Muthusamy K. A., Stein J. F., Aziz T. Z., Johansen-Berg H. (2007). Topography of cortical and subcortical connections of the human pedunculopontine and subthalamic nuclei. Neuroimage 37, 694–705. doi: 10.1016/j.neuroimage.2007.05.050. [PubMed] [Cross Ref]
  • Aravamuthan B. R., Stein J. F., Aziz T. Z. (2008). The anatomy and localization of the pedunculopontine nucleus determined using probabilistic diffusion tractography [corrected]. Br. J. Neurosurg. 22(Suppl. 1), S25–S32. doi: 10.1080/02688690802448251. [PubMed] [Cross Ref]
  • Arnulf I., Ferraye M., Fraix V., Benabid A. L., Chabardès S., Goetz L., et al. (2010). Sleep induced by stimulation in the human pedunculopontine nucleus area. Ann. Neurol. 67, 546–549. doi: 10.1002/ana.21912. [PubMed] [Cross Ref]
  • Aviles-Olmos I., Foltynie T., Panicker J., Cowie D., Limousin P., Hariz M., et al. (2011). Urinary incontinence following deep brain stimulation of the pedunculopontine nucleus. Acta Neurochir. (Wien) 153, 2357–2360. doi: 10.1007/s00701-011-1155-6. [PubMed] [Cross Ref]
  • Ballanger B., Lozano A. M., Moro E., van Eimeren T., Hamani C., Chen R., et al. (2009). Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson’s disease: a [(15)O] H2O PET study. Hum. Brain Mapp. 30, 3901–3909. doi: 10.1002/hbm.20815. [PubMed] [Cross Ref]
  • Benabid A. L., Chabardes S., Mitrofanis J., Pollak P. (2009). Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol. 8, 67–81. doi: 10.1016/S1474-4422(08)70291-6. [PubMed] [Cross Ref]
  • Benarroch E. E. (2013). Pedunculopontine nucleus: functional organization and clinical implications. Neurology 80, 1148–1155. doi: 10.1212/WNL.0b013e3182886a76. [PubMed] [Cross Ref]
  • Bronstein J. M., Tagliati M., Alterman R. L., Lozano A. M., Volkmann J., Stefani A., et al. (2011). Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch. Neurol. 68, 165. doi: 10.1001/archneurol.2010.260. [PubMed] [Cross Ref]
  • Brusa L., Iani C., Ceravolo R., Galati S., Moschella V., Marzetti F., et al. (2009). Implantation of the nucleus tegmenti pedunculopontini in a PSP-P patient: safe procedure, modest benefits. Mov. Disord. 24, 2020–2022. doi: 10.1002/mds.22706. [PubMed] [Cross Ref]
  • Buysse D. J., Reynolds C. F., 3rd, Monk T. H., Berman S. R., Kupfer D. J. (1989). The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatry Res. 28, 193–213. doi: 10.1016/0165-1781(89)90047-4. [PubMed] [Cross Ref]
  • Callaway C. W., Lydic R., Baghdoyan H. A., Hobson J. A. (1987). Pontogeniculooccipital waves: spontaneous visual system activity during rapid eye movement sleep. Cell. Mol. Neurobiol. 7, 105–149. doi: 10.1007/BF00711551. [PubMed] [Cross Ref]
  • Castrioto A., Lozano A. M., Poon Y. Y., Lang A. E., Fallis M., Moro E. (2011). Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch. Neurol. 68, 1550–1556. doi: 10.1001/archneurol.2011.182. [PubMed] [Cross Ref]
  • Ceravolo R., Brusa L., Galati S., Volterrani D., Peppe A., Siciliano G., et al. (2011). Low frequency stimulation of the nucleus tegmenti pedunculopontini increases cortical metabolism in parkinsonian patients. Eur. J. Neurol. 18, 842–849. doi: 10.1111/j.1468-1331.2010.03254.x. [PubMed] [Cross Ref]
  • Chaudhuri K. R., Healy D., Schapira A. H. V. (2006). The non motor symptoms of Parkinson’s disease. Diagnosis and management. Lancet Neurol. 5, 235–245. doi: 10.1016/S1474-4422(06)70373-8. [PubMed] [Cross Ref]
  • Chaudhuri K. R., Pal S., DiMarco A., Whately-Smith C., Bridgman K., Mathew R., et al. (2002). The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatr. 73, 629–635. doi: 10.1136/jnnp.73.6.629. [PMC free article] [PubMed] [Cross Ref]
  • Costa A., Carlesimo G. A., Caltagirone C., Mazzone P., Pierantozzi M., Stefani A., et al. (2010). Effects of deep brain stimulation of the pedunculopontine area on working memory tasks in patientis with Parkinson’s disease. Parkinsonism Relat. Disord. 16, 64–67. doi: 10.1016/j.parkreldis.2009.05.009. [PubMed] [Cross Ref]
  • Daniels C., Krack P., Volkmann J., Pinsker M. O., Krause M., Tronnier V., et al. (2010). Risk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson’s disease. Mov. Disord. 25, 1583–1589. doi: 10.1002/mds.23078. [PubMed] [Cross Ref]
  • Datta S. (1997). Cellular basis of pontine ponto-geniculo-occipital wave generation and modulation. Cell. Mol. Neurobiol. 17, 341–365. doi: 10.1023/A:1026398402985. [PubMed] [Cross Ref]
  • Datta S. (2002). Evidence that REM sleep is controlled by the activation of brain stem pedunculopontine tegmental kainate receptor. J. Neurophysiol. 87, 1790–1798. [PubMed]
  • Datta S. (2006). Activation of phasic pontine-wave generator: a mechanism for sleep-dependent memory processing. Sleep Biol. Rhythms 4, 16–26. doi: 10.1111/j.1479-8425.2006.00202.x. [Cross Ref]
  • Datta S., Siwek D. F. (2002). Single cell activity patterns of pedunculopontine tegmentum neurons across the sleep-wake cycle in the freely moving rats. J. Neurosci. Res. 70, 79–82. doi: 10.1002/jnr.10405. [PubMed] [Cross Ref]
  • Datta S., Spoley E. E., Mavanji V. K., Patterson E. H. (2002). A novel role of pedunculopontine tegmental kainate receptors: a mechanism of rapid eye movement sleep generation in the rat. Neuroscience 114, 157–164. doi: 10.1016/S0306-4522(02)00250-6. [PubMed] [Cross Ref]
  • Fedele E., Mazzone P., Stefani A., Bassi A., Ansaldo M. A., Raiteri M., et al. (2001). Microdialysis in Parkinsonian patient basal ganglia: acute apomorphine-induced clinical and electrophysiological effects not paralleled by changes in the release of neuroactive amino acids. Exp. Neurol. 167, 356–365. doi: 10.1006/exnr.2000.7568. [PubMed] [Cross Ref]
  • Ferraye M. U., Debu B., Fraix V., Goetz L., Ardouin C., Yelnik J., et al. (2010). Effects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s disease. Brain 133, 205–214. doi: 10.1093/brain/awp229. [PubMed] [Cross Ref]
  • Ferraye M. U., Debû B., Fraix V., Krack P., Charbardès S., Seigneuret E., et al. (2011). Subthalamic nucleus versus pedunculopontine nucleus stimulation in Parkinson disease: synergy or antagonism? J. Neural Transm. 118, 1469–1475. doi: 10.1007/s00702-011-0673-y. [PubMed] [Cross Ref]
  • Florio T., Scarnati E., Confalone G., Minchella D., Galati S., Stanzione P., et al. (2007). High-frequency stimulation of the subthalamic nucleus modulates the activity of pedunculopontine neurons through direct activation of excitatory fibres as well as through indirect activation of inhibitory pallidal fibres in the rat. Eur. J. Neurosci. 25, 1174–1186. doi: 10.1111/j.1460-9568.2007.05360.x. [PubMed] [Cross Ref]
  • Follett K. A., Weaver F. M., Stern M., Hur K., Harris C. L., Luo P., et al. (2010). Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N. Engl. J. Med. 362, 2077–2091. doi: 10.1056/NEJMoa0907083. [PubMed] [Cross Ref]
  • Garcia-Rill E., Heister D. S., Ye M., Charlesworth A., Hayar A. (2007). Electrical coupling: novel mechanism for sleep-wake control. Sleep 30, 1405–1414. [PubMed]
  • Garcia-Rill E., Houser C. R., Skinner R. D., Smith W., Woodward D. J. (1987). Locomotion-inducing sites in the vicinity of the pedunculopontine nucleus. Brain Res. Bull. 8, 731–738. doi: 10.1016/0361-9230(87)90208-5. [PubMed] [Cross Ref]
  • Heister D. S., Hayar A., Charlesworth A., Yates C., Zhou Y. H., Garcia-Rill E. (2007). Evidence for electrical coupling in the SubCoeruleus (SubC) nucleus. J. Neurophysiol. 97, 3142–3147. doi: 10.1152/jn.01316.2006. [PMC free article] [PubMed] [Cross Ref]
  • Hilker R., Portman A. T., Voges J., Staal M. J., Burghaus L., van Laar T., et al. (2005). Disease progression continues in patients with advanced Parkinson’s disease and effective subthalamic nucleus stimulation. J. Neurol. Neurosurg. Psychiatr. 76, 1217–1221. doi: 10.1136/jnnp.2004.057893. [PMC free article] [PubMed] [Cross Ref]
  • Hilker R., Voges J., Weisenbach S., Kalbe E., Burghaus L., Ghaemi M., et al. (2004). Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson’s disease. J. Cereb. Blood Flow Metab. 24, 7–16. doi: 10.1097/01.WCB.0000092831.44769.09. [PubMed] [Cross Ref]
  • Hinnell C., Hurt C. S., Landau S., Brown R. G., Samuel M. PROMS-PD Study Group (2012). Nonmotor versus motor symptoms: how much do they matter to health status in Parkinson’s disease? Mov. Disord. 27, 236–241. doi: 10.1002/mds.23961. [PubMed] [Cross Ref]
  • Hirsch E. C., Graybiel A. M., Duyckaerts C., Javoy-Agid F. (1987). Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc. Natl. Acad. Sci. U.S.A. 84, 5976–5980. doi: 10.1073/pnas.84.16.5976. [PubMed] [Cross Ref]
  • Insola A., Valeriani M., Mazzone P. (2012). Targeting the pedunculopontine nucleus: a new neurophysiological method based on somatosensory evoked potentials to calculate the distance of DBS lead from the Obex. Neurosurgery 71(1 Suppl. Operative), 96–103. doi: 10.1227/NEU.0b013e318249c726. [PubMed] [Cross Ref]
  • Jenkinson N., Nandi D., Miall R. C., Stein J. F., Aziz T. Z. (2004). Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey. Neuroreport 15, 2621–2624. doi: 10.1097/00001756-200412030-00012. [PubMed] [Cross Ref]
  • Johns M. W. (1991). A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14, 540–545. [PubMed]
  • Johnson M. D., Miocinovic S., McIntyre C. C., Vitek J. L. (2008). Mechanisms and targets of deep brain stimulation in movement disorders. Neurotherapeutics 5, 294–308. doi: 10.1016/j.nurt.2008.01.010. [PMC free article] [PubMed] [Cross Ref]
  • Khan S., Gill S. S., Mooney L., White P., Whone A., Brooks D. J., et al. (2012). Combined pedunculopontine-subthalamic stimulation in Parkinson disease. Neurology 78, 1090–1095. doi: 10.1212/WNL.0b013e31824e8e96. [PMC free article] [PubMed] [Cross Ref]
  • Kleiner-Fisman G., Fisman D. N., Sime E., Saint-Cyr J. A., Lozano A. M., Lang A. E. (2003). Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J. Neurosurg. 99, 489–495. doi: 10.3171/jns.2003.99.3.0489. [PubMed] [Cross Ref]
  • Kobayashi S., Nakamura Y. (2003). Synaptic organization of the rat parafascicular nucleus, with special reference to its afferents from the superior colliculus and the pedunculopontine tegmental nucleus. Brain Res. 980, 80–91. doi: 10.1016/S0006-8993(03)02921-4. [PubMed] [Cross Ref]
  • Lee M. S., Rinne J. O., Marsden C. D. (2000). The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med. J. 41, 167–184. [PubMed]
  • Lim A. S., Lozano A. M., Moro E., Hamani C., Hutchison W. D., Dostrovsky J. O., et al. (2007). Characterization of REM-sleep associated ponto-geniculo-occipital waves in the human pons. Sleep 30, 823–827. [PubMed]
  • Lim A. S., Moro E., Lozano A. M., Hamani C., Dostrovsky J. O., Hutchison W. D., et al. (2009). Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. Ann. Neurol. 66, 110–114. doi: 10.1002/ana.21631. [PubMed] [Cross Ref]
  • Lu J., Sherman D., Devor M., Saper C. B. (2006). A putative flip-flop switch for control of REM sleep. Nature 441, 589–594. doi: 10.1038/nature04767. [PubMed] [Cross Ref]
  • Mazzone P., Insola A., Lozano A., Galati S., Scarnati E., Peppe A., et al. (2007). Peripeduncular and pedunculopontine nuclei: a dispute on a clinically relevant target. Neuroreport 18, 1407–1408. doi: 10.1097/WNR.0b013e3282638614. [PubMed] [Cross Ref]
  • Mazzone P., Insola A., Valeriani M., Caliandro P., Sposato S., Scarnati E. (2012a). Uncertainty, misunderstanding and the pedunculopontine nucleus: the exhumation of an already buried dispute. Acta Neurochir. (Wien) 154, 1527–1529; author reply 1531–1533. doi: 10.1007/s00701-012-1364-7. [PubMed] [Cross Ref]
  • Mazzone P., Sposato S., Insola A., Scarnati E. (2012b). A commentary on the lead positioning for deep brain stimulation in the pedunculopontine tegmental nucleus in a patient affected by multiple system atrophy. Stereotact. Funct. Neurosurg. 90, 130–133. doi: 10.1159/000334495. [PubMed] [Cross Ref]
  • Mazzone P., Lozano A., Stanzione P., Galati S., Scarnati E., Peppe A., et al. (2005). Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson’s disease. Neuroreport 16, 1877–1881. doi: 10.1097/01.wnr.0000187629.38010.12. [PubMed] [Cross Ref]
  • Mazzone P., Scarnati E., Garcia-Rill E. (2011). Commentary: the pedunculopontine nucleus: clinical experience, basic questions and future directions. J. Neural Transm. 118, 1391–1396. doi: 10.1007/s00702-010-0530-4. [PMC free article] [PubMed] [Cross Ref]
  • Mazzone P., Sposato S., Insola A., Di Lazzaro V., Scarnati E. (2008). Stereotactic surgery of nucleus tegmenti pedunculopontini. Br. J. Neurosurg. 22, S33–S40. doi: 10.1080/02688690802448327. [PubMed] [Cross Ref]
  • McCarley R. W., Hobson J. A. (1975). Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science 189, 58–60. doi: 10.1126/science.1135627. [PubMed] [Cross Ref]
  • Mena-Segovia J., Bolam J. P., Magill P. J. (2004). Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family? Trends Neurosci. 27, 585–588. doi: 10.1016/j.tins.2004.07.009. [PubMed] [Cross Ref]
  • Mena-Segovia J., Micklem B. R., Nair-Roberts R. G., Ungless M. A., Bolam J. P. (2009). GABAergic neuron distribution in the pedunculopontine nucleus defines functional subterritories. J. Comp. Neurol. 51, 397–408. doi: 10.1002/cne.22065. [PubMed] [Cross Ref]
  • Moreau C., Defebvre L., Devos D., Marchetti F., Destee A., Stefani A., et al. (2009). STN versus PPN-DBS for alleviating freezing of gait: toward a frequency modulation approach? Mov. Disord. 24, 2164–2166. doi: 10.1002/mds.22743. [PubMed] [Cross Ref]
  • Moro E., Lozano A. M., Pollak P., Agid Y., Rehncrona S., Volkmann J., et al. (2010a). Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson’s disease. Mov. Disord. 25, 578–586. doi: 10.1002/mds.22735. [PubMed] [Cross Ref]
  • Moro E., Hamani C., Poon Y. Y., Al-Khairallah T., Dostrovsky J. O., Hutchison W. D., et al. (2010b). Unilateral pedunculopontine stimulation improves falls in Parkinson’s disease. Brain 133, 215–224. doi: 10.1093/brain/awp261. [PubMed] [Cross Ref]
  • Munro-Davies L. E., Winter J., Aziz T. Z., Stein J. F. (1999). The role of the pedunculopontine region in basal-ganglia mechanisms of akinesia. Exp. Brain Res. 129, 511–517. doi: 10.1007/s002210050921. [PubMed] [Cross Ref]
  • Nandi D., Aziz T. Z., Giladi N., Winter J., Stein J. F. (2002a). Reversal of akinesia in experimental Parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus. Brain 125, 2418–2430. doi: 10.1093/brain/awf259. [PubMed] [Cross Ref]
  • Nandi D., Liu X., Winter J. L., Aziz T. Z., Stein J. F. (2002b). Deep brain stimulation of the pedunculopontine region in the normal non-human primate. J. Clin. Neurosci. 9, 170–174. doi: 10.1054/jocn.2001.0943. [PubMed] [Cross Ref]
  • Ostrem J. L., Christine C. W., Glass G. A., Schrock L. E., Starr P. A. (2010). Pedunculopontine nucleus deep brain stimulation in a patient with primary progressive freezing gait disorder. Stereotact. Funct. Neurosurg. 88, 51–55. doi: 10.1159/000268742. [PubMed] [Cross Ref]
  • Pahapill P. A., Lozano A. M. (2000). The pedunculopontine nucleus and Parkinson’s disease. Brain 123, 1767–1783. doi: 10.1093/brain/123.9.1767. [PubMed] [Cross Ref]
  • Parent M., Descarries L. (2008). Acetylcholine innervation of the adult rat thalamus: distribution and ultrastructural features in dorsolateral geniculate, parafascicular, and reticular thalamic nuclei. J. Comp. Neurol. 511, 678–691. doi: 10.1002/cne.21868. [PubMed] [Cross Ref]
  • Parsons T. D., Rogers S. A., Braaten A. J., Woods S. P., Trooster A. I. (2006). Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson’d disease: a meta-analysis. Lancet Neurol. 5, 578–588. doi: 10.1016/S1474-4422(06)70475-6. [PubMed] [Cross Ref]
  • Peppe A., Pierantozzi M., Baiamonte V., Moschella V., Caltagirone C., Stanzione P., et al. (2012). Deep brain stimulation of pedunculopontine tegmentum nucleus: role in sleep modulation in advanced Parkinson’s disease patients. One-year follow-up. Sleep 35, 1637–1642. doi: 10.5665/sleep.2234. [PubMed] [Cross Ref]
  • Peppe A., Pierantozzi M., Chiavalon C., Marchetti F., Caltagirone C., Musicco M., et al. (2010). Deep brain stimulation of the pedunculopontine tegmentum and subthalamic nucleus: effects on gait in Parkinson’s disease. Gait Posture 32, 512–528. doi: 10.1016/j.gaitpost.2010.07.012. [PubMed] [Cross Ref]
  • Pereira E. A., Muthusamy K. A., De Pennington N., Joint C. A., Aziz T. Z. (2008). Deep brain stimulation of the pedunculopontine nucleus in Parkinson’s disease. Preliminary experience at Oxford. Br. J. Neurosurg. 22, S41–S44. doi: 10.1080/02688690802448335. [PubMed] [Cross Ref]
  • Piallat B., Chabardès S., Torres N., Fraix V., Goetz L., Seigneuret E., et al. (2009). Gait is associated with an increase in tonic firing of the sub-cuneiform nucleus neurons. Neuroscience 158, 1201–1205. doi: 10.1016/j.neuroscience.2008.10.046. [PubMed] [Cross Ref]
  • Pierantozzi M., Palmieri M. G., Galati S., Stanzione P., Peppe A., Tropepi D., et al. (2008). Pedunculopontine nucleus deep brain stimulation changes spinal cord excitability in Parkinson’s disease patients. J. Neural Transm. 115, 731–735. doi: 10.1007/s00702-007-0001-8. [PubMed] [Cross Ref]
  • Plaha P., Gill S. S. (2005). Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson’s disease. Neuroreport 16, 1883–1887. doi: 10.1097/01.wnr.0000187637.20771.a0. [PubMed] [Cross Ref]
  • Rinne J. O., Ma S. Y., Lee M. S., Collan Y., Ryotta M. (2008). Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson’s disease is related to disability of the patients. Parkinsonism Relat. Disord. 14, 553–557. doi: 10.1016/j.parkreldis.2008.01.006. [PubMed] [Cross Ref]
  • Rodriguez-Oroz M. C., Obeso J. A., Lang A. E., Houeto J. L., Pollak P., Rehncrona S., et al. (2005). Bilateral deep brain stimulation in Parkinson’s disease: a multicentre study with 4 years follow-up. Brain 128, 2240–2249. doi: 10.1093/brain/awh571. [PubMed] [Cross Ref]
  • Romigi A., Placidi F., Peppe A., Pierantozzi M., Izzi F., Brusa L., et al. (2008). Pedunculopontine nucleus stimulation influences REM sleep in Parkinson’s disease. Eur. J. Neurol. 15, e64–e65. doi: 10.1111/j.1468-1331.2008.02167.x. [PubMed] [Cross Ref]
  • Ros H., Magill P. J., Moss J., Bolam J. P., Mena-Segovia J. (2010). Distinct types of non-cholinergic pedunculopontine neurons are differentially modulated during global brain states. Neuroscience 170, 78–91. doi: 10.1016/j.neuroscience.2010.06.068. [PubMed] [Cross Ref]
  • Rye D. B. (1997). Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep 20, 757–788. [PubMed]
  • Scarnati E., Gasbarri A., Campana E., Pacitti C. (1987). The organization of nucleus tegmenti pedunculopontinus neurons projecting to basal ganglia and thalamus: a retrograde fluorescent double labeling study in the rat. Neurosci. Lett. 79, 11–16. doi: 10.1016/0304-3940(87)90664-1. [PubMed] [Cross Ref]
  • Schuepbach W. M., Rau J., Knudsen K., Volkmann J., Krack P., Timmermann L., et al. (2013). Neurostimulation for Parkinson’s disease with early motor complications. N. Engl. J. Med. 368, 610–622. doi: 10.1056/NEJMoa1205158. [PubMed] [Cross Ref]
  • Shimamoto S. A., Larson P. S., Ostrem J. L., Glass G. A., Turner R. S., Starr P. A. (2010). Physiological identification of the human pedunculopontine nucleus. J. Neurol. Neurosurg. Psychiatr. 81, 80–86. doi: 10.1136/jnnp.2009.179069. [PubMed] [Cross Ref]
  • Skinner R. D., Kinjo N., Henderson V., Garcia-Rill E. (1990). Locomotor projections from the pedunculopontine nucleus to the spinal cord. Neuroreport 1, 183–186. doi: 10.1097/00001756-199011000-00001. [PubMed] [Cross Ref]
  • Steckler T., Inglis W., Winn P., Sahgal A. (1994). The pedunculopontine tegmental nucleus: a role in cognitive processes? Brain Res. Brain Res. Rev. 19, 298–318. doi: 10.1016/0165-0173(94)90016-7. [PubMed] [Cross Ref]
  • Stefani A., Fedele E., Galati S., Pepicelli O., Frasca S., Pierantozzi M., et al. (2005). Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients. Ann. Neurol. 57, 448–452. doi: 10.1002/ana.20402. [PubMed] [Cross Ref]
  • Stefani A., Fedele E., Pierantozzi M., Galati S., Marzetti F., Peppe A., et al. (2011). Reduced GABA content in the motor thalamus during effective deep brain stimulation of the subthalamic nucleus. Front. Syst. Neurosci. 5:17. doi: 10.3389/fnsys.2011.00017. [PMC free article] [PubMed] [Cross Ref]
  • Stefani A., Galati S., Pierantozzi M., Peppe A., Brusa L., Moschella V., et al. (2009). “Motor and non-motor effects of PPN-DBS in PD patients: insights from intra-operative electrophysiology,” in The Basal Ganglia IX, Vol. 58, eds Groenewegen H. J., Voorn P., Berendse H. W., Mulder A. B., Cools A. R., editors. (New York: Springer; ), 573–587.
  • Stefani A., Lozano A. M., Peppe A., Stanzione P., Galati S., Tropepi D., et al. (2007). Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s disease. Brain 130, 1596–1607. doi: 10.1093/brain/awl346. [PubMed] [Cross Ref]
  • Stefani A., Olivola E., Stampanoni Bassi M., Pisani V., Imbriani P., Pisani A., et al. (2013). Strenght and weakness of cerebrospinal fluid biomarkers in Alzheimer’s disease and possible detection of overlaps with frailty process. CNS Neurol. Disord. Drug Targets.[Epub ahead of print]. [PubMed]
  • Stefani A., Pierantozzi M., Ceravolo R., Brusa L., Galati S., Stanzione P. (2010). Deep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation? Clin. EEG Neurosci. 41, 82–86. doi: 10.1177/155005941004100207. [PubMed] [Cross Ref]
  • Steriade M., Datta S., Pare D., Oakson G., Curro Dossi R. C. (1990). Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J. Neurosci. 10, 2541–2559. [PubMed]
  • Steriade M., Datta S., Paré D., Oakson G., Curró Dossi R. C. (1990a). Neuronal activities in brain-stem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J. Neurosci. 10, 2541–2559. [PubMed]
  • Steriade M., Paré D., Datta S., Oakson G., Curró Dossi R. (1990b). Different cellular types in mesopontine cholinergic nuclei related to ponto-geniculo-occipital waves. J. Neurosci. 10, 2560–2579. [PubMed]
  • Strafella A. P., Lozano A. M., Ballanger B., Poon Y. Y., Lang A. E., Moro E. (2008). rCBF changes associated with PPN stimulation in a patient with Parkinson’s disease: a PET study. Mov. Disord. 23, 1051–1054. doi: 10.1002/mds.22055. [PubMed] [Cross Ref]
  • Takakusaki K. (2008). Forebrain control of locomotor behaviors. Brain Res. Rev. 57, 192–198. doi: 10.1016/j.brainresrev.2007.06.024. [PubMed] [Cross Ref]
  • Takakusaki K., Habaguchi T., Ohtinata-Sugimoto J., Saitoh K., Sakamoto T. (2003). Basal ganglia efferents to the brainstem centres controlling postural muscle tone and locomotion: a new concept for understanding motor disorders in basal ganglia dysfunction. Neuroscience 119, 293–308. doi: 10.1016/S0306-4522(03)00095-2. [PubMed] [Cross Ref]
  • Thevathasan W., Coyne T. J., Hyam J. A., Kerr G., Jenkinson N., Aziz T. Z., et al. (2011). Pedunculopontine nucleus stimulation improves gait freezing in Parkinson disease. Neurosurgery 69, 1248–1254. doi: 10.1227/NEU.0b013e31822b6f71. [PubMed] [Cross Ref]
  • Thevathasan W., Pogosyan A., Hyam J. A. (2012). Alpha oscillations in the pedunculopontine nucleus correlate with gait performance in Parkinsonism. Brain 135, 148–160. doi: 10.1093/brain/awr315. [PMC free article] [PubMed] [Cross Ref]
  • Thevathasan W., Silburn P. A., Brooker H., Coyne T. J., Khan S., Gill S. S., et al. (2010). The impact of low-frequency stimulation of the pedunculopontine nucleus region on reaction time in Parkinsonism. J. Neurol. Neurosurg. Psychiatr. 81, 1099–1104. doi: 10.1136/jnnp.2009.189324. [PubMed] [Cross Ref]
  • Vitek J. L. (2012). Long-term benefit from deep brain stimulation of the subthalamic nucleus: is it for everyone? Alzheimers Res. Ther. 4, 13. doi: 10.1186/alzrt111. [PMC free article] [PubMed] [Cross Ref]
  • Wang H. L., Morales M. (2009). Pedunculopontine and laterodorsal tegmental nuclei contain distinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat. Eur. J. Neurosci. 29, 340–358. doi: 10.1111/j.1460-9568.2008.06576.x. [PubMed] [Cross Ref]
  • Wilcox R. A., Cole M. H., Wong D., Coyne T., Silburn P., Kerr G. (2011). Pedunculopontine nucleus deep brain stimulation produces sustained improvement in primary progressive freezing of gait. J. Neurol. Neurosurg. Psychiatr. 82, 1256–1259. doi: 10.1136/jnnp.2010.213462. [PubMed] [Cross Ref]
  • Williams A. E., Arzola G. M., Strutt A. M., Simpson R., Jankovic J., York M. K. (2011). Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat. Disord. 17, 321–327. doi: 10.1016/j.parkreldis.2011.01.011. [PMC free article] [PubMed] [Cross Ref]
  • Winn P. (2006). How best to consider the structure and function of the pedunculopontine tegmental nucleus: evidence from animal studies. J. Neurol. Sci. 248, 234–250. doi: 10.1016/j.jns.2006.05.036. [PubMed] [Cross Ref]
  • Witt K., Daniels C., Krack P., Volkmann J., Pinsker M. O., Kloss M., et al. (2011). Negative impact of borderline global cognitive scores on quality of life after subthalamic nucleus stimulation in Parkinson’s disease. J. Neurol. Sci. 310, 261–266. doi: 10.1016/j.jns.2011.06.028. [PubMed] [Cross Ref]
  • Witt K., Daniels C., Reiff J., Krack P., Volkmann J., Pinsker M. O., et al. (2008). Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: a randomised, multicentre study. Lancet Neurol. 7, 605–614. doi: 10.1016/S1474-4422(08)70114-5. [PubMed] [Cross Ref]
  • Zanini S., Moschella V., Stefani A., Peppe A., Pierantozzi M., Galati S., et al. (2009). Grammar improvement following deep brain stimulation of the subthalamic and the pedunculopontine nuclei in advanced Parkinson’s disease: a pilot study. Parkinsonism Relat. Disord. 15, 606–609. doi: 10.1016/j.parkreldis.2008.12.003. [PubMed] [Cross Ref]
  • Zrinzo L., Zrinzo L. V., Tisch S., Limousin P. D., Yousry T. A., Afshar F., et al. (2008). Stereotactic localization of the human pedunculopontine nucleus: atlas-based coordinates and validation of a magnetic resonance imaging protocol for direct localization. Brain 131, 1588–1598. doi: 10.1093/brain/awn075. [PubMed] [Cross Ref]

Articles from Frontiers in Neurology are provided here courtesy of Frontiers Media SA